ARQT — Arcutis Biotherapeutics Share News
0.000.00%
Last trade - 00:00- $3.38bn
- $3.26bn
- $376.07m
Arcutis Q1 product revenue rises 65% yr/yr, net loss narrows
Brief: Arcutis Announces Promotion Of MAS Matsuda To Executive Vice President And Chief Legal Officer To Support Next Phase Of Growth
Brief: Arcutis Begins Enrolling Phase 1A/1B Study Evaluating Arq-234, A Cd200r Agonist, In Healthy Volunteers And Adults With Atopic Dermatitis
Brief: Arcutis Biotherapeutics Inc Files For Mixed Shelf
Brief: Arcutis Announces Fourth Quarter And Full Year 2025 Financial Results
Arcutis Q4 revenue rises 84% on ZORYVE sales, raises FY guidance
Brief: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule
Brief: Arcutis Highlights 2026 Strategic Priorities And Anticipated Milestones
Brief: Arcutis Strengthens Board Of Directors With New Appointment Of Amit Munshi
U.S. RESEARCH ROUNDUP-Biogen, Deere & Co, Sherwin-Williams
Brief: FDA Accepts Supplemental New Drug Application For Arcutis’ Zoryve® (Roflumilast) Cream 0.3% For The Treatment Of Plaque Psoriasis In Children Ages 2 To 5
Brief: Arcutis Canada Says Health Canada Approves ZORYVE Foam 0.3% For Scalp, Body Psoriasis For Adults & Adolescents 12 & Older
Brief: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP-ATI, GoDaddy, Lyft
Arcutis Biotherapeutics' Q3 revenue jumps to $99.2 mln
Brief: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule
Brief: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Arcutis Submits SNDA For Zoryve Cream For Treatment Of Plaque Psoriasis In Children
Brief: Palvella Therapeutics Strengthens Leadership With Appointment Of Accomplished Scientist And Biopharmaceutical Executive David W. Osborne, Ph.D. As Chief Innovation Officer